Straits Times Index
3,290.70 +24.75 (+0.76%) Nikkei
38,229.11 +155.13 (+0.41%) Hang Seng
18,963.68 +425.87 (+2.30%) FTSE 100
8,433.76 +52.41 (+0.63%) Bitcoin USD
60,878.84 -2,048.49 (-3.26%) CMC Crypto 200
1,265.58 -92.42 (-6.81%)
Repare Therapeutics Inc. (RPTX)
After hours:
| Previous close | 3.6400 |
| Open | 3.6600 |
| Bid | 3.5000 x 100 |
| Ask | 3.6000 x 100 |
| Day's range | 3.5000 - 3.7450 |
| 52-week range | 2.9800 - 13.8500 |
| Volume | |
| Avg. volume | 207,898 |
| Market cap | 148.559M |
| Beta (5Y monthly) | 0.56 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.2300 |
| Earnings date | 26 Feb 2024 - 01 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 15.33 |
Simply Wall St.Repare Therapeutics First Quarter 2024 Earnings: Beats Expectations
Repare Therapeutics ( NASDAQ:RPTX ) First Quarter 2024 Results Key Financial Results Revenue: US$52.4m (up by US$46.7m...
- Business Wire
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results
CAMBRIDGE, Mass. & MONTREAL, May 07, 2024--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2024.
- Business Wire
Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition
MONTREAL & LAUSANNE, Switzerland, April 30, 2024--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, and Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to cure cancer and infectious diseases, today announced that the first patient has been dosed in Module 4 of the ongoing Phase 1/1b MYTHIC (NCT04855656) clinical trial investigating lun
